Ascendis Pharma ASASND +2.24%37 Beneish M-Score is 3.38 as of Jun. 25, 2026. GuruFocus rates ASND with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 831 Biotechnology companies, Ascendis Pharma AS ranks worse than 90.61% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 3.38 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Ascendis Pharma AS's Beneish M-Score or its related term are showing as below:
ASND'
s Beneish M-Score Range Over the Past 10 Years
Min: -3.43 Med: -0.94 Max: 48.99
Current: 3.38
During the past 13 years, the highest Beneish M-Score of Ascendis Pharma AS was 48.99. The lowest was -3.43. And the median was -0.94.
Ascendis Pharma AS Beneish M-Score Related Terms
Ascendis Pharma AS Beneish M-Score Historical Data
* Premium members only.
The historical data trend for Ascendis Pharma AS's Beneish M-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASND vs SMMT, BBIO, JAZZ: Beneish M-Score Comparison
For the Biotechnology subindustry, Ascendis Pharma AS's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascendis Pharma AS Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascendis Pharma AS's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Ascendis Pharma AS's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Ascendis Pharma AS for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 1.0703
+
0.528 * 0.9566
+
0.404 * 8.3097
+
0.892 * 2.557
+
0.115 * 1.4125
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.6569
+
4.679 * 0.268666
-
0.327 * 0.645
=
3.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(19.178 / (19.178 + 99.943))
/
(20.214 / (20.214 + 157.131))
=
0.160996
/
0.113981
=
1.4125
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(571.862 - -121.43
-
71.08)
/
2315.929
=
0.268666
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Ascendis Pharma AS has a M-score of 3.38 signals that the company is likely to be a manipulator.
Ascendis Pharma AS (ASND) has a Beneish M-Score of 3.38 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ascendis Pharma AS and its competitors. According to the industry distribution chart, Ascendis Pharma AS ranks #753 out of 831 companies in the Biotechnology industry, placing it in the top 90.6%.
Is Ascendis Pharma AS's Beneish M-Score too high?
Ascendis Pharma AS's current Beneish M-Score is 3.38. Based on the distribution chart, Ascendis Pharma AS ranks #753 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascendis Pharma AS has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Ascendis Pharma AS's Beneish M-Score compare to SMMT and BBIO?
According to the Biotechnology industry distribution chart, Ascendis Pharma AS ranks #753 out of 831 companies for Beneish M-Score. This places Ascendis Pharma AS in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Ascendis Pharma AS and its competitors. Ascendis Pharma AS's current Beneish M-Score is 3.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascendis Pharma AS stock overvalued right now?
Ascendis Pharma AS (ASND) has a current Beneish M-Score of 3.38. The current Beneish M-Score is 3.38. Ascendis Pharma AS's overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Ascendis Pharma AS (ASND), the current Beneish M-Score is 3.38 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
37GF Score
Get the complete analysis for ASND
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASND has been successfully added to your 
